Search

EHA-Balkan Hematology Day 2023

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 4th edition of the EHA-Balkan Hematology Day.

Read more

Myeloproliferative neoplasms better understood through scientific meeting

The EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms held on October 12-14, 2017 in Budapest, Hungary received a 100% recommendation rating from attendees.

Read more

Meeting program

Thursday, October 12*All times are in EET.

Read more

Position of EHA on Personalized Medicine

 

The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

Presentations

EHA-MSH Hematology Tutorial 

Session 1: Basic Principles of Hodgkin Lymphoma

Lecture: MJ Kersten (Not available)
Clinical Case: PL Low (Not available)
Self-assessment case: MJ Kersten (Not available)
Session 2: Histopathology and Diagnosis

Lecture: MA Piris (here)
Clinical Case: CC Liong (here)
Self-assessment case: MA Piris (here)
Session 3: Treatment of Newly Diagnosed Hodgkin Lymphoma

Lecture: A Czyż (here)
Clinical…

Read more

Chairs and members

Chair (2024–2027)
Elizabeth Macintyre, Hôpital Necker-Enfants Malades et Université Paris, France
Vice-Chair (2024–2027)
Margarita Guenova, National Specialised Hospital for Active Treatment of Haematological Diseases, Belgium
Steering Committee (2024–2027)
Monika Brüggemann, University Hospital Kiel, Germany (ESHLO)
Francesco Buccisano, Tor Vergata University of Rome, Italy (SWG on Diagnosis…

Read more

BENIGN HEMATOLOGY in 2023 and beyond

The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.

Read more